Victoza vs. Glimepiride
See how Victoza and Glimepiride compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Victoza is a once-daily injectable GLP-1 receptor agonist that also lowers cardiovascular risk, while glimepiride is a once-daily oral sulfonylurea that only targets blood sugar.
Glimepiride carries a real risk of hypoglycemia and costs far less than Victoza, but Victoza tends to cause fewer blood sugar lows and can support modest weight loss.
Both drugs are approved only for type 2 diabetes, not type 1, and both require gradual dose increases to reduce side effects.
Victoza vs. Glimepiride Drug Summary
Victoza
Victoza (liraglutide) is a GLP-1 receptor agonist injected once daily to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It also carries an FDA approval to reduce major cardiovascular events in adults with type 2 diabetes and existing heart disease. Treatment starts at a low dose that is increased over the first few weeks to limit nausea.
Glimepiride
Glimepiride is an oral sulfonylurea taken once daily to help adults with type 2 diabetes control blood sugar as an adjunct to diet and exercise. It works by prompting the pancreas to release more insulin, with the dose raised gradually from 1 mg up to a maximum of 8 mg. It has been available since 1995 and is one of the most affordable diabetes medications on the market.
Victoza vs. Glimepiride Side Effects
Victoza
Glimepiride
Victoza vs. Glimepiride Dosage
Victoza
Glimepiride
| STAGE | DOSE | WHEN |
| Starting dose | 0.6 mg once daily | Week 1 |
| Maximum dose | 1.8 mg once daily | Week 3 onward |
| Dose changes | 2 increases | Every week |
| STAGE | DOSE | WHEN |
| Starting dose | 1 mg once daily | At the start |
| Maximum dose | 8 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
Victoza
| STAGE | DOSE | WHEN |
| Starting dose | 0.6 mg once daily | Week 1 |
| Maximum dose | 1.8 mg once daily | Week 3 onward |
| Dose changes | 2 increases | Every week |
Glimepiride
| STAGE | DOSE | WHEN |
| Starting dose | 1 mg once daily | At the start |
| Maximum dose | 8 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
Victoza vs. Glimepiride Indications
Victoza
Victoza is FDA-approved to improve blood sugar control in type 2 diabetes for adults and children 10 and older, alongside diet and exercise. It also carries an approval to reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and known heart disease. It is not approved for type 1 diabetes.
Adjunct to diet and exercise for type 2 diabetes
Approved for children 10 years and older
Reduces risk of major cardiovascular events
Not approved for type 1 diabetes
Glimepiride
Glimepiride is FDA-approved to help control blood sugar in adults with type 2 diabetes, used together with diet and exercise. It does not carry a cardiovascular risk-reduction indication and is not approved for type 1 diabetes or diabetic ketoacidosis. It is typically used only in adults.
Adjunct to diet and exercise for type 2 diabetes
Approved only for adults
No cardiovascular risk-reduction indication
Not approved for type 1 diabetes or DKA
Victoza vs. Glimepiride Pros and Cons
Victoza
Victoza offers cardiovascular protection and a lower risk of hypoglycemia than sulfonylureas, but it requires a daily injection and carries a boxed warning for thyroid tumor risk seen in animal studies. Insurance coverage and cost can be significant barriers for many patients.
Pros
Reduces risk of major cardiovascular events
Low risk of causing hypoglycemia on its own
Often leads to modest weight loss
Approved for children 10 and older
Cons
Requires a daily self-injection
Boxed warning for thyroid C-cell tumor risk
Common gastrointestinal side effects like nausea
Roughly $935 to $1,470 per month without insurance
Glimepiride
Glimepiride is an affordable, well-established oral option, but it carries a real risk of hypoglycemia and has been linked to increased cardiovascular mortality in older studies. It has no cardiovascular benefit indication and does not typically cause weight loss.
Pros
Taken as a pill, no injections needed
Roughly $10 to $20 per month without insurance
Long track record dating back to 1995
Simple, predictable oral dosing
Cons
Higher risk of hypoglycemia than Victoza
Possible increased cardiovascular mortality risk
No cardiovascular protective indication
Can cause weight gain
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.